ATE528013T1 - Impfstoff-zusammensetzungen - Google Patents

Impfstoff-zusammensetzungen

Info

Publication number
ATE528013T1
ATE528013T1 AT09706841T AT09706841T ATE528013T1 AT E528013 T1 ATE528013 T1 AT E528013T1 AT 09706841 T AT09706841 T AT 09706841T AT 09706841 T AT09706841 T AT 09706841T AT E528013 T1 ATE528013 T1 AT E528013T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
treatment
relates
hypercytokines
melanoma
Prior art date
Application number
AT09706841T
Other languages
English (en)
Inventor
Andrzej Mackiewicz
Original Assignee
Agirx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agirx Ltd filed Critical Agirx Ltd
Application granted granted Critical
Publication of ATE528013T1 publication Critical patent/ATE528013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT09706841T 2008-01-31 2009-01-30 Impfstoff-zusammensetzungen ATE528013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2008/000780 WO2009095033A1 (en) 2008-01-31 2008-01-31 Vaccine compositons
PCT/EP2009/000626 WO2009095261A2 (en) 2008-01-31 2009-01-30 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE528013T1 true ATE528013T1 (de) 2011-10-15

Family

ID=39264516

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09706841T ATE528013T1 (de) 2008-01-31 2009-01-30 Impfstoff-zusammensetzungen

Country Status (10)

Country Link
US (1) US20110002898A1 (de)
EP (1) EP2252322B1 (de)
JP (1) JP2011511772A (de)
CN (1) CN101965194A (de)
AT (1) ATE528013T1 (de)
AU (1) AU2009210204A1 (de)
CA (1) CA2714554A1 (de)
DK (1) DK2252322T3 (de)
IL (1) IL207310A (de)
WO (2) WO2009095033A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0634460A2 (de) 1993-07-13 1995-01-18 ALBRIGHT & WILSON UK LIMITED Antikorrosive Pigmente
US7972594B2 (en) 2006-11-13 2011-07-05 Immunovative Therapies Ltd. Ablative immunotherapy
WO2009004374A1 (en) 2007-06-29 2009-01-08 Generics [Uk] Limited Process for introduction of hydroxyethoxy side chain in bosentan
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions
US20160022789A1 (en) * 2012-08-15 2016-01-28 Neostem Oncology, Llc Individualized high purity colon carcinoma stem cells, methods and use of the same
US20160058855A1 (en) * 2012-08-15 2016-03-03 Neostem Oncology, Llc High purity ovarian cancer stem cells for active autologous immune therapy
HK1220620A1 (zh) * 2013-03-11 2017-05-12 Neostem Oncology, Llc 诱导和纯化负责血管模仿的细胞群的方法及其用途
AU2014248713A1 (en) * 2013-03-12 2015-09-10 Neostem Oncology, Llc Individualized high-purity glioblastoma multiforme stem cells and methods for stimulating immune response
SG11201507350WA (en) * 2013-03-12 2015-10-29 Immunovative Therapies Ltd Ablative immunotherapy
EP2992898A1 (de) * 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-Zell-Adjuvant und dessen Verwendung zur therapeutischen und prophylaktischen Impfung
US11058752B2 (en) * 2016-11-22 2021-07-13 Alloplex Biotherapeutics Allogeneic tumor cell vaccine
US11320427B2 (en) * 2017-07-13 2022-05-03 Taipei Medical University Tandemly repeated antibody-binding protein and its applications
EP3875111A1 (de) * 2020-03-05 2021-09-08 Poznan University Of Medical Sciences Stammzellkrebsimpfstoffzusammensetzung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406689B1 (en) * 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
WO2000026676A1 (en) * 1998-11-03 2000-05-11 Cell Genesys, Inc. Cancer-associated antigens and methods of their identification
WO2003092579A2 (en) * 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
EP1598364A1 (de) * 2004-05-21 2005-11-23 AGIRx Limited Chimerischer löslicher Hyper IL-11 Rezeptor und dessen Verwendung

Also Published As

Publication number Publication date
EP2252322B1 (de) 2011-10-12
CA2714554A1 (en) 2009-08-06
DK2252322T3 (da) 2012-01-30
WO2009095261A3 (en) 2009-09-24
IL207310A0 (en) 2010-12-30
US20110002898A1 (en) 2011-01-06
CN101965194A (zh) 2011-02-02
WO2009095033A1 (en) 2009-08-06
EP2252322A2 (de) 2010-11-24
JP2011511772A (ja) 2011-04-14
IL207310A (en) 2016-06-30
AU2009210204A1 (en) 2009-08-06
WO2009095261A2 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
DK2252322T3 (da) Vaccinesammensætninger
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
TR201907783T4 (tr) Benzosulfonamit türevleri, bileşimleri ve kanser hücrelerinin metastazının önlenmesinde kullanımları.
EA201590987A1 (ru) Соединения и способы их применения
EA201101522A1 (ru) Способы лечения болезней с использованием эпиметаболического переключателя (коэнзим q10)
PH12014501639A1 (en) Pharmaceutical compositions and methods
MY191825A (en) Therapeutic compounds and compositions
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
IN2012DN01920A (de)
MX366318B (es) Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
CO6551693A2 (es) Composiciones para tratar naúseas y vómito centralmente mediados
CR20110553A (es) Terapia complementaria contra el cáncer
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
EP4582090A3 (de) Zusammensetzung mit pegylierter arginin-deiminase
MX394137B (es) Compuestos y composiciones novedosas para atacar las células madre del cáncer.
MX2015001551A (es) Compuestos y composiciones activadoras de enzima.
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
EP2597949A4 (de) Submikrometerzusammensetzungen
GB2528604A (en) Modulation of asymmetric proliferation
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
TN2012000552A1 (en) An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2575766A4 (de) Neue pharmazeutische verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2252322

Country of ref document: EP